A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

• Status: RECRUITING
• Trial end date: 2026-12-15

Summary

Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.

• Phase: PHASE1

Details

• Lead Sponsor: West China Hospital
• Treatments: Afatinib; Biological Factors; Immunotherapy; tislelizumab